Literature DB >> 19480391

Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry.

Daniel K Rogstad1, Jason L Herring, Jacob A Theruvathu, Artur Burdzy, Christopher C Perry, Jonathan W Neidigh, Lawrence C Sowers.   

Abstract

The nucleoside analogue 5-aza-2'-deoxycytidine (Decitabine, DAC) is one of several drugs in clinical use that inhibit DNA methyltransferases, leading to a decrease of 5-methylcytosine in newly replicated DNA and subsequent transcriptional activation of genes silenced by cytosine methylation. In addition to methyltransferase inhibition, DAC has demonstrated toxicity and potential mutagenicity, and can induce a DNA-repair response. The mechanisms accounting for these events are not well understood. DAC is chemically unstable in aqueous solutions, but there is little consensus between previous reports as to its half-life and corresponding products of decomposition at physiological temperature and pH, potentially confounding studies on its mechanism of action and long-term use in humans. Here, we have employed a battery of analytical methods to estimate kinetic rates and to characterize DAC decomposition products under conditions of physiological temperature and pH. Our results indicate that DAC decomposes into a plethora of products, formed by hydrolytic opening and deformylation of the triazine ring, in addition to anomerization and possibly other changes in the sugar ring structure. We also discuss the advantages and problems associated with each analytical method used. The results reported here will facilitate ongoing studies and clinical trials aimed at understanding the mechanisms of action, toxicity, and possible mutagenicity of DAC and related analogues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19480391      PMCID: PMC3985229          DOI: 10.1021/tx900131u

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  33 in total

1.  Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.

Authors:  A R Karpf; B C Moore; T O Ririe; D A Jones
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

2.  Convenient method for the preparation of 2'-deoxyribosylurea by thymidine oxidation and NMR study of both anomers.

Authors:  I Dubey; G Pratviel; A Robert; B Meunier
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2001-08       Impact factor: 1.381

Review 3.  Biological consequences of free radical-damaged DNA bases.

Authors:  Susan S Wallace
Journal:  Free Radic Biol Med       Date:  2002-07-01       Impact factor: 7.376

4.  Nucleotide formation from alpha- and beta-2'-deoxythioguanosine in extracts of murine and human tissues.

Authors:  A Peery; G A LePage
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

5.  Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions.

Authors:  R E Notari; J L DeYoung
Journal:  J Pharm Sci       Date:  1975-07       Impact factor: 3.534

6.  Amidinourea formate, a precursor of 2-amino-4-hydroxy-s-triazine.

Authors:  R Hartenstein; I Fridovich
Journal:  J Org Chem       Date:  1967-05       Impact factor: 4.354

7.  Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.

Authors:  Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Francis J Giles; Stefan Faderl; Jean-Pierre Issa; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Michael Andreeff; Michael Keating; Moshe Talpaz
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

8.  Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.

Authors:  Michael Daskalakis; Tudung T Nguyen; Carvell Nguyen; Per Guldberg; Gabriele Köhler; Pierre Wijermans; Peter A Jones; Michael Lübbert
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

9.  Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.

Authors:  J A Beisler
Journal:  J Med Chem       Date:  1978-02       Impact factor: 7.446

Review 10.  5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.

Authors:  Judith K Christman
Journal:  Oncogene       Date:  2002-08-12       Impact factor: 9.867

View more
  30 in total

1.  Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus.

Authors:  Zhenbo Hu; Soledad Negrotto; Xiaorong Gu; Reda Mahfouz; Kwok Peng Ng; Quteba Ebrahem; Edward Copelan; Harinder Singh; Jaroslaw P Maciejewski; Yogen Saunthararajah
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

2.  Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.

Authors:  Christine L Clouser; Laurent Bonnac; Louis M Mansky; Steven E Patterson
Journal:  Antivir Chem Chemother       Date:  2014-12-16

3.  Age-related macular degeneration (AMD) mitochondria modulate epigenetic mechanisms in retinal pigment epithelial cells.

Authors:  Sonali Nashine; Anthony B Nesburn; Baruch D Kuppermann; M Cristina Kenney
Journal:  Exp Eye Res       Date:  2019-06-19       Impact factor: 3.467

4.  5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.

Authors:  Jonathan M Rawson; Richard H Heineman; Lauren B Beach; Jessica L Martin; Erica K Schnettler; Michael J Dapp; Steven E Patterson; Louis M Mansky
Journal:  Bioorg Med Chem       Date:  2013-08-20       Impact factor: 3.641

5.  Concomitant lethal mutagenesis of human immunodeficiency virus type 1.

Authors:  Michael J Dapp; Colleen M Holtz; Louis M Mansky
Journal:  J Mol Biol       Date:  2012-03-15       Impact factor: 5.469

6.  p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.

Authors:  K P Ng; Q Ebrahem; S Negrotto; R Z Mahfouz; K A Link; Z Hu; X Gu; A Advani; M Kalaycio; R Sobecks; M Sekeres; E Copelan; T Radivoyevitch; J Maciejewski; J C Mulloy; Y Saunthararajah
Journal:  Leukemia       Date:  2011-06-24       Impact factor: 11.528

7.  Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine.

Authors:  Jaideep V Thottassery; Vijaya Sambandam; Paula W Allan; Joseph A Maddry; Yulia Y Maxuitenko; Kamal Tiwari; Melinda Hollingshead; William B Parker
Journal:  Cancer Chemother Pharmacol       Date:  2014-06-08       Impact factor: 3.333

8.  A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine.

Authors:  Lauren B Levine; Julianna Vf Roddy; Miryoung Kim; Junan Li; Gary Phillips; Alison R Walker
Journal:  J Oncol Pharm Pract       Date:  2017-03-26       Impact factor: 1.809

9.  Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.

Authors:  Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

10.  Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesis.

Authors:  Jonathan M O Rawson; Sean R Landman; Cavan S Reilly; Laurent Bonnac; Steven E Patterson; Louis M Mansky
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.